ストックスクリーナーアプリを入手
1.8455
2.35%
-0.0445
前日終値:
$1.89
開ける：
$1.98
24時間の取引高:
36,649
Relative Volume:
0.54
時価総額：
$5.11M
収益：
-
当期純損益:
$-14.11M
株価収益率:
-0.1722
EPS:
-10.7181
ネットキャッシュフロー:
$-13.60M
1週間 パフォーマンス:
-5.84%
1か月 パフォーマンス:
-23.74%
6か月 パフォーマンス:
-46.66%
1年 パフォーマンス:
-65.24%
1日の値動き範囲:
$1.6701
$2.031
1週間の範囲:
$1.6701
$2.3799
52週間の値動き範囲:
$1.6701
$14.24
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
名前
Processa Pharmaceuticals Inc
セクター
電話
443-776-3133
住所
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
1.8455 | 5.23M | 0 | -14.11M | -13.60M | -10.72 |
VRTX
Vertex Pharmaceuticals Inc
|
511.62 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.74 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.55 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.20 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.00 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-25 | 開始されました | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc (PCSA) 最新ニュース
Insider Buying: Russell Skibsted Acquires Additional Shares of P - GuruFocus
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock - Investing.com
Processa Pharmaceuticals CEO George Ng acquires $5,900 in stock By Investing.com - Investing.com Nigeria
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Insider purchase: Processa (NASDAQ: PCSA) CAO adds 2,436 shares in open-market buy - Stock Titan
Processa (PCSA) strategy chief adds 2,106 shares in insider buy - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 3,057 shares in open-market buy - Stock Titan
CFO of Processa (NASDAQ: PCSA) adds 3,277 shares in open-market buy - Stock Titan
Processa Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SKIBSTED RUSSELL - Moomoo
Processa Pharmaceuticals (PCSA) director buys 2,531 shares in open market - Stock Titan
Processa Pharmaceuticals, Inc. Financial Disclosures & SEC Filings - TradingView
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Processa (NASDAQ: PCSA) director Yorke vests 203-share restricted stock award - Stock Titan
[Form 4] Processa Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Processa Pharmaceuticals (PCSA) director receives 203 shares from vesting - Stock Titan
Processa Pharmaceuticals (PCSA) director gets 203 shares from service award - Stock Titan
Price to sales forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Price to earnings forward of Processa Pharmaceuticals, Inc. – NASDAQ:PCSA - TradingView
Processa Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:PCSA) - TradingView
PCSA | Processa Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
Shareholders to vote on Processa (NASDAQ: PCSA) equity plan and pay - Stock Titan
Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Processa Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Processa Pharmaceuticals Inc (PCSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Processa Pharmaceuticals Inc (PCSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Processa Pharmaceuticals Inc - TradingKey
Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Processa Pharmaceuticals Inc (PCSA) Institutional Confidence - TradingKey
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock By Investing.com - Investing.com UK
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock By Investing.com - Investing.com India
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock By Investing.com - Investing.com Australia
Processa Pharmaceuticals CFO Russell Skibsted buys $5,891 in stock - Investing.com
Processa Pharmaceuticals chief business officer Lin buys $4,064 stock - Investing.com UK
Processa Pharmaceuticals CEO George Ng buys $5,472 in stock - Investing.com UK
Processa Pharma president of R&D David Young buys $4,588 in stock - Investing.com Canada
Processa Pharma president of R&D David Young buys $4,588 in stock By Investing.com - Investing.com South Africa
Insider David Young adds 2,067 Processa (PCSA) shares at $2.22 - Stock Titan
Processa Pharmaceuticals (PCSA) CFO buys 2,654 shares in open market - Stock Titan
Processa Pharmaceuticals (PCSA) CEO adds 2,465 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) officer adds 1,831 shares in open-market buy - Stock Titan
Processa Pharmaceuticals (PCSA) CAO buys 2,118 shares at $2.22 in open market - Stock Titan
PCSA Q4 2025 Earnings: EPS Misses Estimates by 67.97% as Pre-Revenue Biotech Faces HeadwindsWeak Earnings Momentum - newsline.com
Processa Pharmaceuticals, Inc. - MLQ.ai
PCSA Stock Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
PCSA Stock Price, Quote & Chart | PROCESSA PHARMACEUTICALS INC (NASDAQ:PCSA) - ChartMill
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals CAO Wendy Guy buys $4,700 in stock - Investing.com
Processa Pharmaceuticals’ pres. David Young buys $4,590 in stock By Investing.com - Investing.com India
Processa Pharmaceuticals Inc (PCSA) 財務データ
収益
当期純利益
現金流量
EPS
Processa Pharmaceuticals Inc (PCSA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lin Patrick | Chief Business - Strategy Off |
Jun 30 '26 |
Buy |
1.93 |
2,106 |
4,065 |
13,113 |
| Ng George K | Chief Executive Officer |
Jul 01 '26 |
Buy |
1.93 |
3,057 |
5,900 |
15,492 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 30 '26 |
Buy |
1.93 |
3,277 |
6,325 |
16,689 |
| Young David | Pres. Research & Development |
Jun 30 '26 |
Buy |
1.93 |
2,531 |
4,885 |
21,729 |
| Young David | Pres. Research & Development |
Jun 15 '26 |
Buy |
2.22 |
2,067 |
4,589 |
19,198 |
| SKIBSTED RUSSELL | Chief Financial Officer |
Jun 15 '26 |
Buy |
2.22 |
2,654 |
5,892 |
13,412 |
| Ng George K | Chief Executive Officer |
Jun 15 '26 |
Buy |
2.22 |
2,465 |
5,472 |
12,435 |
| Lin Patrick | Chief Business - Strategy Off |
Jun 15 '26 |
Buy |
2.22 |
1,831 |
4,065 |
11,007 |
| Guy Wendy | Chief Administrative Officer |
Jun 15 '26 |
Buy |
2.22 |
2,118 |
4,702 |
11,958 |
| Young David | Pres. Research & Development |
May 29 '26 |
Buy |
2.57 |
1,786 |
4,590 |
17,131 |
1.26%
2.31%
大文字化:
|
ボリューム (24 時間):